Lung Cancer, Small Cell Clinical Trial
Official title:
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin + Pemetrexed or Cisplatin + Pemetrexed
This is a Phase II, randomized, open-label, multi-center study in advanced (Stage IVA and IVB subjects per the International Association for the Study of Lung Cancer (IASLC) 2009 Lung cancer staging schema) non-squamous NSCLC subjects comparing pazopanib relative to pemetrexed in the maintenance setting. Subjects should have completed 4-6 cycles of induction therapy with carboplatin + pemetrexed or cisplatin + pemetrexed and have had Stable Disease (SD), Partial Response (PR) or Complete Response (CR) as the best response to be enrolled into the study. The primary objective is to estimate the hazard ratio of progression free survival (PFS) in advanced NSCLC subjects given maintenance therapy of pazopanib (Arm A) relative to pemetrexed (Arm B). The secondary objectives are: overall survival, response rates, safety and tolerability. A total of approximately 200 subjects will be enrolled and randomized in a 1:1 ratio. Safety and efficacy assessments will be regularly performed on all subjects.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00046111 -
A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Enrolling by invitation |
NCT06293833 -
Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan
|
N/A | |
| Completed |
NCT00259935 -
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01037023 -
Regulatory Hycamtin(Oral) PMS
|
N/A | |
| Active, not recruiting |
NCT04986670 -
NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer
|
N/A | |
| Completed |
NCT00997061 -
SCOT Registry: Small Cell Lung Cancer Treatment and Outcome
|
N/A | |
| Completed |
NCT00276276 -
Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT05320458 -
Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer
|
N/A | |
| Active, not recruiting |
NCT05228496 -
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC
|
Phase 2 | |
| Completed |
NCT00316186 -
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
|
Phase 2 | |
| Not yet recruiting |
NCT04440800 -
Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Treatment
|
||
| Completed |
NCT00698516 -
Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT03499678 -
Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA
|
||
| Active, not recruiting |
NCT04660929 -
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
|
Phase 1 | |
| Completed |
NCT00320359 -
Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT00043862 -
The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)
|
Phase 2 | |
| Recruiting |
NCT06228326 -
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
|
Phase 1 | |
| Completed |
NCT04314895 -
Trial of NanoPac Intratumoral Injection in Lung Cancer
|
Phase 2 |